Jason Hawkes, MD, MS, provided an in-depth look at the potential role of dupilumab (Dupixent; Sanofi and Regeneron ...

As a result, there is no need to give the first three doses in clinic. Further, dupilumab works on different mechanisms of CSU pathogenesis, blocking the effects of key cytokines involved in CSU ...

The US Food and Drug Administration (FDA) has approved dupilumab for the treatment of chronic spontaneous urticaria (CSU) in patients aged 12 years and older who “remain symptomatic despite H1 ...